New therapeutic targets for ACE inhibitors and angiotensin receptor blockers;Nowatorskie zastosowania inhibitorów konwertazy angiotensyny i antagonistów receptora angiotensyny II

Polskie Archiwum Medycyny Wewnetrznej

Volumn 117, Issue 4, 2007, Pages 44-50

  Petkow Dimitrow, Paweł ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

ACE inhibitors; Angiotensin; Angiotensin receptor blockers

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; RAMIPRIL; TELMISARTAN;

AORTA RUPTURE; BRAIN CIRCULATION; BRAIN PROTECTION; DRUG INDICATION; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART PROTECTION; HYPERTENSION; MARFAN SYNDROME; METABOLIC SYNDROME X; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STROKE; SUDDEN DEATH; VASODILATATION;

EID: 34547806221     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Dahlof B, Devereux RB, Kjeldsen SE, et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention ForEndpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359: 995-1003.
2. Papademetriou V, Farsang C, Elmfeldt D, et al. Study on Cognition and Prognosis in the Elderly study group. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004; 44: 1175-1180.
3. Schrader J, Luders S, Kulschewski A, et al. MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005; 36: 1218-1226.
4. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004; 364: 1684-1689.
5. The PROGRESS Collaborative Group: randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001; 358: 1033-1041.
6. The PATS Collaborating Group: Post-stroke Antihypertensive Treatment Study. Chinese Med J. 1995; 108: 710-717.
7. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288: 2981-2997.
8. Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005; 46: 386-392.
9. Fournier A, Messerli FH, Achard JM, et al. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol. 2004; 43: 1343-1347.
10. Messerli FH, Simbo M, Chiadika A. Stroke Prevention: Not all Antihypertensive Drugs are Created Equal. J Renin Angiotensin Aldosterone Syst. 2005; 6 (Suppl 1): S4-S7.
11. Szczepańska-Sadowska E. Układ reninia-angiotensyna- aldosteron. In: Januszewicz A, Januszewicz W, Szczepańska-Sadowska E, Sznajderman M, eds. Nadciśnienie tȩtnicze. Kraków, Medycyna Praktyczna, 2004: 193-209.
12. Szczepańska-Sadowska E. Fizjologíczne i patofizjologiczne znaczenie receptorów dla angiotensyny. In: Januszewicz A, Januszewicz W, Rużyłło W, eds. Antagoniści receptora angiotensyny II w leczeniu chorób układu sercowo-naczyniowego. Kraków, Medycyna Praktyczna, 2006: 57-73.
13. Levy BI. Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system. Circulation. 2004; 109: 8-13.
14. Unger T. The angiotensin type 2 receptor: variations on an enigmatic theme. J Hypertens. 1999; 17: 1775-1786.
15. Gainer JV, Morrow JD, Loucland A, et al. Effect of bradykinin-receptor blockade on the response to angiotensinconverting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med. 1998; 339: 1285-1292.
16. Schulz R, Heusch G. Angiotensin II type 1 receptors in cerebral ischaemia-reperfusion: initiation of inflammation. J Hypertens Suppl. 2006; 24: S123-S129.
17. Barone FC, Coatney RW, Chandra S, et al. Eprosartan reduces cardiac hypertrophy, protects heart and kidney, and prevents early mortality in severely hypertensive stroke-prone rats. Cardiovasc Res. 2001; 50: 525-537.
18. Rutkowski B, Tylicki L. Antagoniści receptora angiotensyny II- terapia skojarzona z inhibitorami konwertazy angiotensyny. In: Januszewicz A, Januszewicz W, Rużyłło W, eds. Antagoniści receptora angiotensyny II w leczeniu chorób układu sercowo-naczyniowego. Kraków, Medycyna Praktyczna, 2006: 333-346.
19. Biollaz J, Brunner HR, Gavras I, et al. Antihypertensive therapy with MK 421: angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982; 4: 966-972.
20. Roig E, Perez-Villa F, Morales M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J. 2000; 21: 53-57.
21. 1A receptor. Circulation. 2004; 110: 3849-3857.
22. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system inpatients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br Med J. 2000; 321: 1440-1444.
23. Jacobsen P, Andersen S, Rossing K, et al. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney Int. 2003; 63: 1874-1880.
24. Tylicki L, Rutkowski P, Renke M, et al. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation. Am J Nephrol. 2002; 22: 356-362.
25. Kincaid-Smith P, Fairley K, Packham D. Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant. 2002; 17: 597-601.
26. Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet. 2003; 361: 117-124.
27. Gaciong Z. New therapeutic options in renal diseases - hypotensive therapy. Pol Arch Med Wewn. 2004; 112: 57-63.
28. 1 inhibitors in used in the progression of chronic renal failure. Pol Arch Med Wewn. 2002; 107: 379-387.
29. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345: 1667-1675.
30. McMurray JJ, Ostergren J, Swedberg K, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003; 362: 767-771.
31. Roik M, Starczewska MH, Stawicki S, et al. Effect of the optimal neurohormonal blockade on long-term survival in patients with chronic heart failure. Pol Arch Med Wewn. 2006; 115: 321-328.
32. Struthers AD. Angiotensin blockade or aldosterone blockade as the third neuroendocrineblocking drug in mild but symptomatic heart failure patients. Heart 2006; 92: 1728-1731.
33. Małecki R, Świtalskí M, Małecka L, et al. Heart failure in advanced age. Pol Arch Med Wewn. 2004; 112: 125-138.
34. Kasma S, Toyama T, Hatori T, et al. Comparative effects of valsartan and enalapril on cardiac sympathetic nerve activity and plasma brain natriuretic peptide in patients with congestive heart failure. Heart. 2006; 92: 625-630.
35. Brown MJ. Renin: friend or foe? Heart. 2007 May 8; [Epub ahead of print].
36. Olsen MH, Fossum E, Hoieggen A, et al. Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens. 2005; 23: 891-898.
37. Lindholm LH, Persson M, Alaupovic P, et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003; 21: 1563-1574.
38. Goette A, Lendeckel U, Klein HU. Signal transduction systems and atrial fibrillation. Cardiovasc Res. 2002; 54: 247-258.
39. Ehrlich JR, Hohnloser SH, Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J. 2006; 27: 512-518.
40. Goette A, Staack T, Rocken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol. 2000; 35: 1669-1677.
41. Nakashima H, Kumagai K, Urata H, et al. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation. 2000; 101: 2612-2617.
42. Macrez N, Morel JL, Kalkbrenner F, et al. A betagamma dimer derived from G13 transduces the angiotensin AT1 receptor signal to stimulation of Ca2+ channels in rat portal vein myocytes. J Biol Chem. 1997; 272: 23180-23185.
43. Shi Y, Li D, Tardif JC, et al. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res. 2002; 54: 456-461.
44. L'Allier PL, Ducharme A, Keller PF, et al. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation. J Am Coll Cardiol. 2004; 44: 159-164.
45. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation. 2003; 107: 2926-2931.
46. Alsheikh-Ali AA, Wang PJ, Rand W, et al. Enalapril treatment and hospitalization with atrial tachyarrhythmias in patients with left ventricular dysfunction. Am Heart J. 2004; 147: 1061-1065.
47. Murray KT, Rottman JN, Arbogast PG, et al. Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm. 2004; 1: 669-675.
48. Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J. 2003; 24: 2090-2098.
49. Yin Y, Dalal D, Liu Z, et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J. 2006; 27: 1841-1846.
50. 1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006; 312: 117-121.